ING Groep NV Takes $1.94 Million Position in Hologic, Inc. $HOLX

ING Groep NV bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 28,754 shares of the medical equipment provider’s stock, valued at approximately $1,941,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Winnow Wealth LLC acquired a new position in Hologic during the third quarter worth $26,000. Caitong International Asset Management Co. Ltd raised its position in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the last quarter. Root Financial Partners LLC acquired a new stake in Hologic in the 3rd quarter worth about $27,000. SJS Investment Consulting Inc. increased its stake in Hologic by 341.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 362 shares in the last quarter. Finally, Loomis Sayles & Co. L P purchased a new position in shares of Hologic in the second quarter valued at approximately $33,000. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their target price for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Raymond James Financial downgraded shares of Hologic from a “moderate buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Leerink Partners upped their price objective on shares of Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research note on Tuesday, October 21st. Finally, BTIG Research reissued a “neutral” rating on shares of Hologic in a research note on Tuesday, October 21st. Two investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, Hologic has a consensus rating of “Hold” and an average price target of $78.42.

Hologic Stock Performance

Hologic stock opened at $75.04 on Friday. The firm has a 50 day simple moving average of $74.89 and a 200-day simple moving average of $71.55. The stock has a market cap of $16.75 billion, a price-to-earnings ratio of 31.27, a price-to-earnings-growth ratio of 2.23 and a beta of 0.72. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $75.36.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.07 billion. Hologic had a net margin of 13.18% and a return on equity of 19.58%. The firm’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.87 EPS. On average, analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.